Department of Physiology, Kangwon National University School of Medicine, Chuncheon 24341, South Korea.
Department of Urology, Kangwon National University School of Medicine, Chuncheon 24341, South Korea.
Life Sci. 2021 Dec 15;287:120101. doi: 10.1016/j.lfs.2021.120101. Epub 2021 Oct 29.
Canagliflozin is an anti-diabetic agent and sodium glucose co-transporter-2 inhibitor. Despite numerous clinical trials demonstrating its beneficial effects on blood pressure, the cellular mechanisms underlying the effects of canagliflozin on vascular reactivity have yet to be clarified. We investigated the vasodilatory effect of canagliflozin on aortic rings isolated from rabbits.
We used rabbit thoracic aortic rings and its arterial tone was tested by using wire myography system.
Canagliflozin caused concentration-dependent vasodilation in aortic rings pre-constricted with phenylephrine or high K. However, the degree of canagliflozin-induced vasodilation of the aortic rings pre-constricted with high K was less than that of rings pre-constricted with phenylephrine. Application of 4-aminopyridine, a voltage-dependent K (Kv) channel inhibitor, reduced canagliflozin-induced vasodilation. However, pre-incubation of an inwardly rectifying K channel inhibitor, a large-conductance Ca-activated K channel inhibitor, and an ATP-sensitive K inhibitor did not modulate the vasodilatory effects of canagliflozin. Indeed, canagliflozin increased Kv currents in aortic smooth muscle cells. Pre-treatment with thapsigargin or cyclopiazonic acid, a sarco/endoplasmic reticulum Ca-ATPase (SERCA) pump inhibitors, reduced the vasodilatory effects of canagliflozin. Conversely, pre-treatment with a Ca channel inhibitor, adenylyl cyclase/PKA inhibitors, and guanylyl cyclase/PKG inhibitors did not modulate the vasodilatory effects of canagliflozin. Endothelium removal, and pre-treatment with the nitric oxide synthase inhibitor L-NAME, and small- and intermediate-conductance Ca-activated K channel inhibitor apamin and TRAM-34, did not diminish the vasodilatory effects of canagliflozin.
Our results indicate that canagliflozin induces vasodilation, which is dependent on the robust SERCA activity and Kv channel activation.
卡格列净是一种抗糖尿病药物和钠-葡萄糖协同转运蛋白 2 抑制剂。尽管有许多临床试验表明其对血压有益,但卡格列净对血管反应性影响的细胞机制尚未阐明。我们研究了卡格列净对兔胸主动脉环的血管舒张作用。
我们使用兔胸主动脉环,通过电生理记录仪系统检测其动脉张力。
卡格列净可浓度依赖性地舒张预先用苯肾上腺素或高钾预收缩的主动脉环。然而,卡格列净对高钾预收缩的主动脉环的舒张程度小于对苯肾上腺素预收缩的主动脉环。4-氨基吡啶,一种电压依赖性钾(Kv)通道抑制剂,可降低卡格列净诱导的血管舒张作用。然而,内向整流钾通道抑制剂、大电导钙激活钾通道抑制剂和三磷酸腺苷敏感钾通道抑制剂的预孵育并不能调节卡格列净的血管舒张作用。事实上,卡格列净增加了主动脉平滑肌细胞中的 Kv 电流。预先用肌浆网/内质网 Ca-ATP 酶(SERCA)泵抑制剂 thapsigargin 或 cyclopiazonic acid 处理可降低卡格列净的血管舒张作用。相反,预先用钙通道抑制剂、腺苷酸环化酶/PKA 抑制剂和鸟苷酸环化酶/PKG 抑制剂处理并不调节卡格列净的血管舒张作用。内皮去除,以及预先用一氧化氮合酶抑制剂 L-NAME、小电导和中电导钙激活钾通道抑制剂 apamin 和 TRAM-34 处理,并不减弱卡格列净的血管舒张作用。
我们的结果表明,卡格列净诱导的血管舒张依赖于强大的 SERCA 活性和 Kv 通道激活。